Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities:
Net loss	$ (247,740)	$ (283,746)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,201	7,631
Expensed in-process research and development	2,679
Premium amortization and discount accretion on investment securities	1,450	2,960
Stock-based compensation	85,165	76,060
Non-cash lease expense	7,451	6,652
Amortization of debt discount and issuance cost	642	625
Foreign exchange adjustment	265	7
Loss on investments		203
Non-cash interest expense	68	32
Changes in operating assets and liabilities:
Accounts receivable	(15,680)	(86,237)
Inventory	(7,281)	(3,556)
Prepaid expenses and other assets	12,590	4,727
Accounts payable	(9,018)	2,492
Accrued compensation	9,936	(7,982)
Operating lease liabilities	(5,196)	(5,528)
Other accrued liabilities	(11,175)	29,525
Deferred revenue	6,368	8,009
Cash used in operating activities	(159,275)	(248,126)
Investing activities:
Purchases of investments		(79,956)
Proceeds from sale of investments		191,939
Proceeds from maturity of investments	83,250	153,500
Purchases of property and equipment, net	(20,566)	(23,661)
Cash provided by investing activities	62,684	241,822
Financing activities:
Proceeds from exercise of stock options	2,939	4,578
Proceeds from issuance of common stock under employee stock purchase plan	8,674	8,496
Cash provided by financing activities	11,613	13,074
Net change in cash, cash equivalents and restricted cash	(84,978)	6,770
Cash, cash equivalents and restricted cash, beginning of period	466,091	84,614
Cash, cash equivalents and restricted cash, end of period	381,113	91,384
Supplemental disclosure of cash flow information:
Cash paid for interest	5,596	3,612
Non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accruals	103	$ 2,035
Issuance of common stock for IPR&D acquisition	14,435
Issuance of common stock for bonuses	$ 19,771